Bioresorbable alginate derivatives

Details Bioresorbable alginate derivatives Bioresorbable alginate derivatives

1997-12-18

2002-08-27

Gitomer, Ralph (Department: 1623)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C514S054000, C536S003000, C424S445000

Reexamination Certificate

active

06440940

ABSTRACT:

BACKGROUND
The present invention relates to bioresorbable alginate derivatives and processes for the production thereof. The present invention also relates to the use of such bioresorbable alginate derivatives in pharmaceutical compositions, especially wound dressings, implants and surgical prostheses.
Alginates are linear binary copolymers of D-mannuronic acid (MA) and L-guluronic acid (CA) having the structures shown in FIG.
1
. The polymers are built up by ether linkages joining the 1- and 4- positions of the MA and GA saccharide residues. Alginates are isolated from marine brown algae, and such naturally occurring alginates generally comprise blocks of MA rich units. GA rich units and mixed sequences of MA and GA units. Commercially available alginates of this type typically contain about 45% of MA.
Alginates are available in the form of alginic acid, various salts, and various ester derivatives such as propyleneglycol alginates. Alginate salts with monovalent cations such as sodium are generally soluble in water. Alginate salts formed with divalent or trivalent cations such as calcium or zinc are generally insoluble in water. The solubility of alginate compositions can thus be controlled over a wide range by varying the sodium/calcium ratio of mixed sodium/calcium alginate salt. Commercially available alginate products are generally formed from such mixed salts.
Alginate products have long been used in the field of wound healing, especially as a packing material for cavity wounds or for treatment of burns. Alginate materials are sold under the registered trade marks KALTOSTAT (Britcaire Limited), SORBSAN (Pharma-Plast Limited) and ALGOSTERIL (Johnson & Johnson). These products are available in a number of forms, including ropes and pads. These materials are highly absorbent, biocompatible and cheap.
Although alginates have good properties for treating cavity wounds and burns, care has to be taken when changing the dressings to ensure that nothing is left in the wound. Alginate is not bioresorbable, but does tend to fragment. If left in the wound, fragments of alginate will result in the formation of granulomas. It is therefore necessary to rinse the wound out thoroughly with saline solution to ensure that no residual alginate remains.
Alginates have also been shown to have excellent haemostatic properties, but because they are not resorbable they must be removed prior to closure of a wound, which inevitably limits their usefulness in this application.
Accordingly, there exists a need for improved materials, in particular for wound dressing and haemostatic applications, that exhibit the advantages of alginates and are also bioresorbable.
It has long been known that cellulose can be rendered bioresorbable by exposure to an oxidizing agent such as dinitrogen tetroxide, as described in U.S. Pat. No. 3,122,479. The resulting oxidized regenerated cellulose (ORC) is available in the form of a knitted fabric under the registered trade mark SURGICEL for use as an absorbable haemostat. ORC is also available under the registered trade mark INTERCEED for use as an adhesion barrier. The bioresorbable character of ORC is thought to be due to oxidation of the primary hydroxyl groups on the cellulose residues to carboxylate groups.
U.S. Pat. No. 4,543,410 describes absorbent, coherent, flexible structures in the form of fibrous webs and porous sponges comprising water-insoluble, ring oxidized cellulosic bases. It is stated that ring oxidation of the cellulosic bases can selectively convert the hydroxyl groups at the 2, 3 and 6 positions of the anhydroglucose units of cellulose into carboxyl groups, depending on the specific oxidant used. It is stated that dinitrogen tetroxide converts the hydroxyl group at the 6 position into a carboxyl group to product a mono-carboxyl form of the base (as in the formation of ORC). Periodic acid will open the ring between the 2 and 3 position and convert the hydroxyl groups at the 2 and 3 position into aldehyde groups. The resulting dioxide can be further oxidized with chlorine or dinitrogen tetroxide to product a dicarboxyl or tricarboxyl form of the base. It is stated that ring oxidized cellulosic base sponges having a carboxyl content due to ring oxidation greater than about 15% are haemostatic and bioresorbable. Ring oxidation of starch is also disclosed.
SUMMARY OF THE INVENTION
It has now been found that ring oxidation of alginates with oxidizing agents such as dinitrogen tetroxide results in bioresorbable, oxidized alginate derivatives. This result is surprising, since the saccharide residues making up the alginate molecules are already fully oxidized to carboxylate at the 6 position before treatment with the dinitrogen tetroxide.
Accordingly, the present invention provides an oxidized alginate.
Preferably, at least part of the MA and/or GA saccharide residues of the alginate have been oxidized at the 2- or 3- position. Such oxidation could take place without ring opening, by oxidation of the secondary alcohol groups to keto groups, or it can take place with ring opening to dialdehyde or dicarboxylate derivatives. More preferably, at least 0.2% of the saccharide residues of the alginate have been oxidized at the 2- or 3- position, and still more preferably at least 1.0% of the saccharide residues have been so oxidized.
Preferably, the ring oxidation of the alginate residues has taken place with ring opening to dicarboxylic acid derivatives. As a result, the oxidized alginate according to the present invention preferably has a carboxylate content greater than that of the starting alginic acid. Preferably, the carboxylate content is increased by at least 1%, and more preferably there is at least 2% increase in the number of carboxylate groups relative to the corresponding unoxidized material. The carboxylate content is determined as follows:
A sample of oxidized alginate (approximately 0.2 g) is dissolved in 0.5M sodium hydroxide (5 ml) and a couple of drops of 0.1% phenolphthalein indicator solution are added. The excess sodium hydroxide is back-titrated with 0.1M HCl to the phenolphthalein end point (red to clear). A blank value is determined by titrating 5 ml 0.1M sodium hydroxide with 0.1M HCl. The value for carboxyl content (percentage by weight) is calculated using the equation:
C
=
4.5
×
(
B
-
S
)
×
M
W
wherein:
C=percent carboxyl content
B=volume of standard HCl to titrate blank (ml)
S=volume of standard HCl to titrate sample (ml)
M=molality of standard HCl
M=dry weight of sample (g)
(4.5=milliequivalent weight of carboxyl×100)
The oxidized alginate is more bioabsorbable and bioassimilable in the mammalian body. Preferably, the oxidized alginate is fully absorbable when implanted in the mammalian body.
The oxidized alginate derivatives according to the present invention have substantially similar solubility behaviour to naturally occurring alginates. In particular, the solubility of oxidized alginate salts can be varied by varying the ratio of sodium and calcium cations. Preferably, the oxidized alginates according to the present invention are substantially insoluble in water. This implies that the oxidized alginates according to the present invention is preferably a salt of the oxidized alginate and divalent of trivalent cations, such as calcium or zinc ions.
Preferably, the oxidized alginates according to the present invention have a weight average molecular weight in the range 10,000 to 1,000,000, more preferably 50,000 to 400,000.
The present invention also provides a pharmaceutical composition comprising an oxidized alginate according to the invention. The invention also provides a wound dressing, surgical implant or prosthesis comprising an oxidized alginate according to the invention, and the use of such an oxidized alginate for the preparation of a wound dressing, surgical implant or prosthesis.
In another aspect, the present invention provides a method of treating a wound in a mammalian body, comprising applying to the wound a wound dressing comprising an oxidized algina

Affiliated with

Also associated with

Rating

Bioresorbable alginate derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Bioresorbable alginate derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Bioresorbable alginate derivatives will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2910389